The global exosomes diagnostic and therapeutic market is poised for significant growth, with projections indicating an increase from USD 88.56 million in 2024 to USD 211.6 million by 2034. This substantial expansion is anticipated to be driven by a robust Compound Annual Growth Rate (CAGR) of 9.10% over the next decade.
Exosomes, small vesicles released by cells, are gaining prominence in the healthcare sector due to their potential in diagnostic and therapeutic applications. As healthcare providers worldwide strive to enhance service accessibility amidst rising patient numbers, laboratories are increasingly adopting informatics-integrated solutions. These innovations are aimed at optimizing productivity and resource utilization within healthcare facilities.
Request A Sample Copy of This Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-6379
Manufacturers in the exosomes market are seizing opportunities by enhancing their product offerings with integrated healthcare solutions. This strategic approach not only supports diagnostic advancements but also contributes significantly to market growth.
Key players in the industry are also leveraging partnerships with academic institutions to drive research and development of novel non-invasive diagnostic tools, particularly for cancer detection. This collaborative effort underscores a commitment to advancing healthcare solutions that are both effective and patient-friendly.
The upward trajectory of the exosomes market reflects growing confidence in non-invasive diagnostic technologies and their potential to revolutionize healthcare delivery worldwide. With continued innovation and strategic collaborations, the market is poised to meet evolving healthcare demands and improve patient outcomes globally.
“Growing investors’ appetite for exosome technology as well as increasing research studies that investigate exosomes and their applications are expected to propel market growth,” says an analyst of Future Market Insights.
Key Takeaways from the Exosomes Diagnostic and Therapeutic Market Report:
- The exosomes diagnostic and therapeutic industry attained a revenue of USD 23.3 million in 2018. The market grew to be worth USD 72.6 million in 2023, recording a CAGR of 25.5%.
- By product type, the instruments segment accounted for a market share of 25% in 2023.
- Based on application, the diagnostics segment acquired a share of 68% in the year 2023.
- The Canada exosomes diagnostic and therapeutic industry is projected to expand at a CAGR of 5% through 2034, whereas the United States market is anticipated to record a CAGR of 4.5% during this period.
- In Germany, the market is forecast to observe a demand rate of 3.8% from 2024 to 2034.
- In Asia Pacific, India and China are expected to expand at CAGRs of 9.5% and 10%, respectively, over the forecast period.
Customization with Our Report: https://www.futuremarketinsights.com/customization-available/rep-gb-6379
Competitive Landscape:
Numerous biopharma companies are offering to create exosome-based therapeutics for an extensive range of conditions. Apart from this, they are meditating on their manufacturing needs. For instance, in 2021, Lonza, a healthcare manufacturing giant purchased the exosome manufacturing unit of the now-inoperative Codiak BioSciences.
CMDOs or Contract Development and Manufacturing Organizations such as RoosterBio have increased their services and joined other companies to resolve bottlenecks in exosome manufacturing. This trend is spreading in Europe, where exosome-based therapeutics developer EXO Biologics introduced a CDMO named ExoXpert to promote their proprietary platforms as a service to other players.
Latest Developments in the Exosomes Diagnostic and Therapeutic Market:
- In July 2023, ExoCoBio, a market leader in exosome technology, acquired BENEV, which is a global medical aesthetic brand. The combination of both these countries is going to create synergistic effects to accelerate the commercialization of exosome technology the world over.
- In January 2024, Aruna Bio officially declared that it had received FDA clearance of IND for Lead Program AB126, which positions it as the first exosome to enter human clinical trials for a neurological indication. FDA’s validation also underscores the therapeutic feasibility of Aruna Bio’s platform.
Key Players in the Exosomes Diagnostic and Therapeutic Market:
- Thermo Fisher Scientific
- NanoSomix
- NX Pharmagen
- Malvern Instruments
- Capricor Therapeutic
- Exosome Diagnostics
- Exiqon A/S
- System Biosciences
- Exosome Sciences
- Aegle Therapeutic
- AMS Biotechnology
- Miltenyi Biotec
- Codiak BioSciences Inc.
- Lonza Group (HansaBioMed Life Sciences Ltd.)
- AcouSort AB
- Aethlon Medical, Inc.
- AGC Biologics
- Anjarium Biosciences AG
- Aruna Bio
- Brexogen
- Capricor Therapeutics
- Cells for Cells
- Ciloa
- ConvEyXO
- Others
A Comprehensive Full Report: https://www.futuremarketinsights.com/checkout/6379
Exosomes Diagnostic and Therapeutic Market Research by Categories:
By Products for Exosomes Diagnostic and Therapeutic are as follows:
- Instruments
- Software
- Reagents and Kits
The Market is Bifurcated Based on Applications as:
- Diagnostics
- Therapeutic
Key End Users of Exosomes Diagnostic and Therapeutic are:
- Hospitals
- Cancer Institutes
- Diagnostic Centers
- Others
Different Markets for Exosomes Diagnostic and Therapeutic are:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
